nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Doxorubicin—thyroid cancer	0.735	1	CbGbCtD
Deferoxamine—Corneal opacity—Vandetanib—thyroid cancer	0.0165	0.0622	CcSEcCtD
Deferoxamine—Chromaturia—Vandetanib—thyroid cancer	0.012	0.0455	CcSEcCtD
Deferoxamine—Pyelonephritis—Vandetanib—thyroid cancer	0.0113	0.0427	CcSEcCtD
Deferoxamine—Visual acuity reduced—Vandetanib—thyroid cancer	0.00722	0.0273	CcSEcCtD
Deferoxamine—Serum creatinine increased—Vandetanib—thyroid cancer	0.00698	0.0264	CcSEcCtD
Deferoxamine—Respiratory distress—Sorafenib—thyroid cancer	0.00456	0.0172	CcSEcCtD
Deferoxamine—Cataract—Vandetanib—thyroid cancer	0.00451	0.0171	CcSEcCtD
Deferoxamine—Bone disorder—Sorafenib—thyroid cancer	0.00321	0.0121	CcSEcCtD
Deferoxamine—Blood creatinine increased—Vandetanib—thyroid cancer	0.00292	0.011	CcSEcCtD
Deferoxamine—Neuropathy—Sorafenib—thyroid cancer	0.00272	0.0103	CcSEcCtD
Deferoxamine—Dysuria—Vandetanib—thyroid cancer	0.00252	0.00952	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00241	0.0091	CcSEcCtD
Deferoxamine—Infestation NOS—Vandetanib—thyroid cancer	0.0024	0.00908	CcSEcCtD
Deferoxamine—Infestation—Vandetanib—thyroid cancer	0.0024	0.00908	CcSEcCtD
Deferoxamine—Renal failure—Vandetanib—thyroid cancer	0.00236	0.00893	CcSEcCtD
Deferoxamine—Renal failure acute—Sorafenib—thyroid cancer	0.00228	0.00861	CcSEcCtD
Deferoxamine—Bradycardia—Vandetanib—thyroid cancer	0.0022	0.0083	CcSEcCtD
Deferoxamine—Urinary tract disorder—Vandetanib—thyroid cancer	0.00213	0.00805	CcSEcCtD
Deferoxamine—Urethral disorder—Vandetanib—thyroid cancer	0.00211	0.00799	CcSEcCtD
Deferoxamine—Visual impairment—Vandetanib—thyroid cancer	0.00208	0.00786	CcSEcCtD
Deferoxamine—Eye disorder—Vandetanib—thyroid cancer	0.00202	0.00762	CcSEcCtD
Deferoxamine—Angiopathy—Vandetanib—thyroid cancer	0.00196	0.0074	CcSEcCtD
Deferoxamine—Mediastinal disorder—Vandetanib—thyroid cancer	0.00194	0.00735	CcSEcCtD
Deferoxamine—Blindness—Epirubicin—thyroid cancer	0.00193	0.00731	CcSEcCtD
Deferoxamine—Local reaction—Epirubicin—thyroid cancer	0.00193	0.00731	CcSEcCtD
Deferoxamine—Arrhythmia—Vandetanib—thyroid cancer	0.00193	0.00728	CcSEcCtD
Deferoxamine—Muscle spasms—Vandetanib—thyroid cancer	0.00181	0.00682	CcSEcCtD
Deferoxamine—Local reaction—Doxorubicin—thyroid cancer	0.00179	0.00676	CcSEcCtD
Deferoxamine—Blindness—Doxorubicin—thyroid cancer	0.00179	0.00676	CcSEcCtD
Deferoxamine—Vision blurred—Vandetanib—thyroid cancer	0.00177	0.00669	CcSEcCtD
Deferoxamine—Transaminases increased—Epirubicin—thyroid cancer	0.00176	0.00665	CcSEcCtD
Deferoxamine—Abdominal discomfort—Sorafenib—thyroid cancer	0.00174	0.00659	CcSEcCtD
Deferoxamine—Optic neuritis—Epirubicin—thyroid cancer	0.00174	0.00658	CcSEcCtD
Deferoxamine—Serum creatinine increased—Epirubicin—thyroid cancer	0.00174	0.00658	CcSEcCtD
Deferoxamine—Transaminases increased—Doxorubicin—thyroid cancer	0.00163	0.00616	CcSEcCtD
Deferoxamine—Convulsion—Vandetanib—thyroid cancer	0.00163	0.00615	CcSEcCtD
Deferoxamine—Infestation NOS—Sorafenib—thyroid cancer	0.00162	0.00613	CcSEcCtD
Deferoxamine—Infestation—Sorafenib—thyroid cancer	0.00162	0.00613	CcSEcCtD
Deferoxamine—Optic neuritis—Doxorubicin—thyroid cancer	0.00161	0.00609	CcSEcCtD
Deferoxamine—Serum creatinine increased—Doxorubicin—thyroid cancer	0.00161	0.00609	CcSEcCtD
Deferoxamine—Arthralgia—Vandetanib—thyroid cancer	0.0016	0.00604	CcSEcCtD
Deferoxamine—Renal failure—Sorafenib—thyroid cancer	0.00159	0.00602	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00159	0.006	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00159	0.006	CcSEcCtD
Deferoxamine—Oedema—Vandetanib—thyroid cancer	0.00153	0.00579	CcSEcCtD
Deferoxamine—Infection—Vandetanib—thyroid cancer	0.00152	0.00575	CcSEcCtD
Deferoxamine—Nervous system disorder—Vandetanib—thyroid cancer	0.0015	0.00568	CcSEcCtD
Deferoxamine—Thrombocytopenia—Vandetanib—thyroid cancer	0.0015	0.00567	CcSEcCtD
Deferoxamine—Skin disorder—Vandetanib—thyroid cancer	0.00149	0.00563	CcSEcCtD
Deferoxamine—Urinary tract disorder—Sorafenib—thyroid cancer	0.00144	0.00543	CcSEcCtD
Deferoxamine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00143	0.0054	CcSEcCtD
Deferoxamine—Urethral disorder—Sorafenib—thyroid cancer	0.00143	0.00539	CcSEcCtD
Deferoxamine—Scotoma—Epirubicin—thyroid cancer	0.00141	0.00533	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.0014	0.00528	CcSEcCtD
Deferoxamine—Paraesthesia—Vandetanib—thyroid cancer	0.00138	0.0052	CcSEcCtD
Deferoxamine—Dyspnoea—Vandetanib—thyroid cancer	0.00137	0.00516	CcSEcCtD
Deferoxamine—Tinnitus—Sorafenib—thyroid cancer	0.00136	0.00513	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00132	0.005	CcSEcCtD
Deferoxamine—Angiopathy—Sorafenib—thyroid cancer	0.00132	0.00499	CcSEcCtD
Deferoxamine—Immune system disorder—Sorafenib—thyroid cancer	0.00131	0.00497	CcSEcCtD
Deferoxamine—Injection site pain—Epirubicin—thyroid cancer	0.00131	0.00496	CcSEcCtD
Deferoxamine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00131	0.00496	CcSEcCtD
Deferoxamine—Pain—Vandetanib—thyroid cancer	0.00131	0.00495	CcSEcCtD
Deferoxamine—Scotoma—Doxorubicin—thyroid cancer	0.0013	0.00493	CcSEcCtD
Deferoxamine—Arrhythmia—Sorafenib—thyroid cancer	0.0013	0.00491	CcSEcCtD
Deferoxamine—Blood disorder—Epirubicin—thyroid cancer	0.00128	0.00485	CcSEcCtD
Deferoxamine—Erythema—Sorafenib—thyroid cancer	0.00127	0.00479	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00125	0.00474	CcSEcCtD
Deferoxamine—Muscle spasms—Sorafenib—thyroid cancer	0.00122	0.0046	CcSEcCtD
Deferoxamine—Injection site pain—Doxorubicin—thyroid cancer	0.00121	0.00459	CcSEcCtD
Deferoxamine—Abdominal pain—Vandetanib—thyroid cancer	0.00121	0.00458	CcSEcCtD
Deferoxamine—Body temperature increased—Vandetanib—thyroid cancer	0.00121	0.00458	CcSEcCtD
Deferoxamine—Blood disorder—Doxorubicin—thyroid cancer	0.00119	0.00448	CcSEcCtD
Deferoxamine—Bone disorder—Epirubicin—thyroid cancer	0.00119	0.00448	CcSEcCtD
Deferoxamine—Angioedema—Sorafenib—thyroid cancer	0.00116	0.00437	CcSEcCtD
Deferoxamine—Leukopenia—Sorafenib—thyroid cancer	0.00113	0.00429	CcSEcCtD
Deferoxamine—Bone pain—Epirubicin—thyroid cancer	0.00112	0.00422	CcSEcCtD
Deferoxamine—Bone disorder—Doxorubicin—thyroid cancer	0.0011	0.00415	CcSEcCtD
Deferoxamine—Pruritus—Vandetanib—thyroid cancer	0.00108	0.0041	CcSEcCtD
Deferoxamine—Arthralgia—Sorafenib—thyroid cancer	0.00108	0.00408	CcSEcCtD
Deferoxamine—Myalgia—Sorafenib—thyroid cancer	0.00108	0.00408	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00107	0.00405	CcSEcCtD
Deferoxamine—Injection site reaction—Epirubicin—thyroid cancer	0.00106	0.00402	CcSEcCtD
Deferoxamine—Diarrhoea—Vandetanib—thyroid cancer	0.00105	0.00396	CcSEcCtD
Deferoxamine—Bone pain—Doxorubicin—thyroid cancer	0.00103	0.00391	CcSEcCtD
Deferoxamine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00103	0.00391	CcSEcCtD
Deferoxamine—Infection—Sorafenib—thyroid cancer	0.00103	0.00388	CcSEcCtD
Deferoxamine—Shock—Sorafenib—thyroid cancer	0.00102	0.00384	CcSEcCtD
Deferoxamine—Nervous system disorder—Sorafenib—thyroid cancer	0.00101	0.00383	CcSEcCtD
Deferoxamine—Dizziness—Vandetanib—thyroid cancer	0.00101	0.00383	CcSEcCtD
Deferoxamine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00101	0.00383	CcSEcCtD
Deferoxamine—Neuropathy—Epirubicin—thyroid cancer	0.00101	0.0038	CcSEcCtD
Deferoxamine—Skin disorder—Sorafenib—thyroid cancer	0.001	0.0038	CcSEcCtD
Deferoxamine—Injection site reaction—Doxorubicin—thyroid cancer	0.000985	0.00372	CcSEcCtD
Deferoxamine—Cramps of lower extremities—Epirubicin—thyroid cancer	0.000984	0.00372	CcSEcCtD
Deferoxamine—Vomiting—Vandetanib—thyroid cancer	0.000974	0.00368	CcSEcCtD
Deferoxamine—Headache—Vandetanib—thyroid cancer	0.00096	0.00363	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000942	0.00356	CcSEcCtD
Deferoxamine—Neuropathy—Doxorubicin—thyroid cancer	0.00093	0.00352	CcSEcCtD
Deferoxamine—Dyspnoea—Sorafenib—thyroid cancer	0.000922	0.00348	CcSEcCtD
Deferoxamine—Nausea—Vandetanib—thyroid cancer	0.00091	0.00344	CcSEcCtD
Deferoxamine—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.00091	0.00344	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000893	0.00337	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00089	0.00336	CcSEcCtD
Deferoxamine—Pain—Sorafenib—thyroid cancer	0.000884	0.00334	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000845	0.00319	CcSEcCtD
Deferoxamine—Renal failure acute—Epirubicin—thyroid cancer	0.000842	0.00318	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000823	0.00311	CcSEcCtD
Deferoxamine—Urticaria—Sorafenib—thyroid cancer	0.000821	0.0031	CcSEcCtD
Deferoxamine—Abdominal pain—Sorafenib—thyroid cancer	0.000817	0.00309	CcSEcCtD
Deferoxamine—Body temperature increased—Sorafenib—thyroid cancer	0.000817	0.00309	CcSEcCtD
Deferoxamine—Renal impairment—Epirubicin—thyroid cancer	0.000817	0.00309	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000803	0.00304	CcSEcCtD
Deferoxamine—Renal failure acute—Doxorubicin—thyroid cancer	0.000779	0.00294	CcSEcCtD
Deferoxamine—Hypersensitivity—Sorafenib—thyroid cancer	0.000762	0.00288	CcSEcCtD
Deferoxamine—Renal impairment—Doxorubicin—thyroid cancer	0.000756	0.00286	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000743	0.00281	CcSEcCtD
Deferoxamine—Pruritus—Sorafenib—thyroid cancer	0.000731	0.00276	CcSEcCtD
Deferoxamine—Blood creatinine increased—Epirubicin—thyroid cancer	0.000728	0.00275	CcSEcCtD
Deferoxamine—Diarrhoea—Sorafenib—thyroid cancer	0.000707	0.00267	CcSEcCtD
Deferoxamine—Dizziness—Sorafenib—thyroid cancer	0.000684	0.00258	CcSEcCtD
Deferoxamine—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000674	0.00255	CcSEcCtD
Deferoxamine—Asthma—Epirubicin—thyroid cancer	0.000672	0.00254	CcSEcCtD
Deferoxamine—Eosinophilia—Epirubicin—thyroid cancer	0.000665	0.00251	CcSEcCtD
Deferoxamine—Vomiting—Sorafenib—thyroid cancer	0.000657	0.00248	CcSEcCtD
Deferoxamine—Headache—Sorafenib—thyroid cancer	0.000648	0.00245	CcSEcCtD
Deferoxamine—Dysuria—Epirubicin—thyroid cancer	0.000628	0.00237	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—thyroid cancer	0.000622	0.00235	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—thyroid cancer	0.000616	0.00233	CcSEcCtD
Deferoxamine—Nausea—Sorafenib—thyroid cancer	0.000614	0.00232	CcSEcCtD
Deferoxamine—Infestation NOS—Epirubicin—thyroid cancer	0.000599	0.00226	CcSEcCtD
Deferoxamine—Infestation—Epirubicin—thyroid cancer	0.000599	0.00226	CcSEcCtD
Deferoxamine—Renal failure—Epirubicin—thyroid cancer	0.000589	0.00223	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000587	0.00222	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—thyroid cancer	0.000581	0.0022	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—thyroid cancer	0.000554	0.00209	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—thyroid cancer	0.000554	0.00209	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—thyroid cancer	0.000548	0.00207	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—thyroid cancer	0.000545	0.00206	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000543	0.00205	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—thyroid cancer	0.000531	0.00201	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000528	0.002	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—thyroid cancer	0.000527	0.00199	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—thyroid cancer	0.000518	0.00196	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—thyroid cancer	0.000507	0.00191	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—thyroid cancer	0.000503	0.0019	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—thyroid cancer	0.000501	0.00189	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000491	0.00186	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000489	0.00185	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—thyroid cancer	0.000488	0.00184	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—thyroid cancer	0.000488	0.00184	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—thyroid cancer	0.000486	0.00184	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000485	0.00183	CcSEcCtD
Deferoxamine—Arrhythmia—Epirubicin—thyroid cancer	0.00048	0.00182	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—thyroid cancer	0.00048	0.00181	CcSEcCtD
Deferoxamine—Erythema—Epirubicin—thyroid cancer	0.000468	0.00177	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—thyroid cancer	0.000465	0.00176	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—thyroid cancer	0.000464	0.00175	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—thyroid cancer	0.000451	0.00171	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—thyroid cancer	0.00045	0.0017	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—thyroid cancer	0.000449	0.0017	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000448	0.00169	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—thyroid cancer	0.000445	0.00168	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—thyroid cancer	0.000441	0.00167	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—thyroid cancer	0.000433	0.00164	CcSEcCtD
Deferoxamine—Leukopenia—Epirubicin—thyroid cancer	0.000419	0.00158	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—thyroid cancer	0.000416	0.00157	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—thyroid cancer	0.000408	0.00154	CcSEcCtD
Deferoxamine—Convulsion—Epirubicin—thyroid cancer	0.000406	0.00153	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—thyroid cancer	0.000399	0.00151	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—thyroid cancer	0.000399	0.00151	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000396	0.0015	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—thyroid cancer	0.000388	0.00147	CcSEcCtD
Deferoxamine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000382	0.00144	CcSEcCtD
Deferoxamine—Oedema—Epirubicin—thyroid cancer	0.000382	0.00144	CcSEcCtD
Deferoxamine—Infection—Epirubicin—thyroid cancer	0.00038	0.00143	CcSEcCtD
Deferoxamine—Shock—Epirubicin—thyroid cancer	0.000376	0.00142	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—thyroid cancer	0.000375	0.00142	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—thyroid cancer	0.000375	0.00142	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000374	0.00141	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—thyroid cancer	0.000373	0.00141	CcSEcCtD
Deferoxamine—Skin disorder—Epirubicin—thyroid cancer	0.000371	0.0014	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—thyroid cancer	0.000369	0.00139	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—thyroid cancer	0.000369	0.00139	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000366	0.00138	CcSEcCtD
Deferoxamine—Hypotension—Epirubicin—thyroid cancer	0.000357	0.00135	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000354	0.00134	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—thyroid cancer	0.000354	0.00134	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—thyroid cancer	0.000351	0.00133	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000348	0.00132	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—thyroid cancer	0.000348	0.00131	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000347	0.00131	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000346	0.00131	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—thyroid cancer	0.000345	0.0013	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—thyroid cancer	0.000343	0.0013	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—thyroid cancer	0.000343	0.0013	CcSEcCtD
Deferoxamine—Dyspnoea—Epirubicin—thyroid cancer	0.000341	0.00129	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—thyroid cancer	0.00033	0.00125	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00033	0.00125	CcSEcCtD
Deferoxamine—Pain—Epirubicin—thyroid cancer	0.000327	0.00123	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000322	0.00122	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—thyroid cancer	0.000317	0.0012	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—thyroid cancer	0.000315	0.00119	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000312	0.00118	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000305	0.00115	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—thyroid cancer	0.000304	0.00115	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—thyroid cancer	0.000302	0.00114	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—thyroid cancer	0.000302	0.00114	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—thyroid cancer	0.000302	0.00114	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000289	0.00109	CcSEcCtD
Deferoxamine—Hypersensitivity—Epirubicin—thyroid cancer	0.000282	0.00106	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—thyroid cancer	0.000281	0.00106	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—thyroid cancer	0.000279	0.00106	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—thyroid cancer	0.000279	0.00106	CcSEcCtD
Deferoxamine—Pruritus—Epirubicin—thyroid cancer	0.00027	0.00102	CcSEcCtD
Deferoxamine—Diarrhoea—Epirubicin—thyroid cancer	0.000261	0.000988	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—thyroid cancer	0.00026	0.000984	CcSEcCtD
Deferoxamine—Dizziness—Epirubicin—thyroid cancer	0.000253	0.000955	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—thyroid cancer	0.00025	0.000945	CcSEcCtD
Deferoxamine—Vomiting—Epirubicin—thyroid cancer	0.000243	0.000918	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—thyroid cancer	0.000242	0.000914	CcSEcCtD
Deferoxamine—Headache—Epirubicin—thyroid cancer	0.000239	0.000905	CcSEcCtD
Deferoxamine—Dizziness—Doxorubicin—thyroid cancer	0.000234	0.000883	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—thyroid cancer	0.000227	0.000858	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—thyroid cancer	0.000225	0.000849	CcSEcCtD
Deferoxamine—Headache—Doxorubicin—thyroid cancer	0.000221	0.000837	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—thyroid cancer	0.00021	0.000794	CcSEcCtD
